GL

Glass House Brands Inc.

GLASHealthcareNASDAQ

Drug Manufacturers - Specialty & Generic · Last scanned Oct 24, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$182.0M
-9.4% YoY
Net Income
-$29.7M
-5814.6% YoY
EBITDA
$5.8M
-83.6% YoY
Free Cash Flow
-$19.8M

Scan Results

Daily timeframe
4 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Oct 20CONFIRMED▲ RSI OversoldRSI 4.0, below 30, stock may be oversold
Oct 19▲ RSI OversoldRSI 4.7, below 30, stock may be oversold
About Glass House Brands Inc.

Headquartered within the healthcare sector, Glass House Brands Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Glass House Brands Inc., together with its subsidiaries, operates as an integrated cannabis company in the United States. With a market capitalization of $201.7M, it sits in micro-cap territory. It operates through three segments: Retail; Wholesale Biomass; and Cannabis-Related Consumer Packaged Goods.

Where GLAS stands vs its 150-day and 200-day moving averages

As of the October 20, 2026 close, GLAS finished 73.61% below its 150-day moving average ($9.32) and 73.03% below its 200-day moving average ($9.12). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is GLAS overbought or oversold?

At the October 20, 2026 close, GLAS's RSI(14) was 4.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$201.7M
Fwd P/E-35.67
EPS$-0.74
Beta0.77
52W Change-72.4%
Dividend Yield0.00%
ROE-28.6%
Analysis

The company holds $18.6M in cash, though total debt stands at $72.3M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$19.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -28.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $84.9M (2022) to $182.0M (2025), reflecting a 114% increase over the period.

The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing GLAS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms